Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Japanese patients with advanced renal cell carcinoma
NCT00661375Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2004
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in renal cell carcinoma (RCC), sponsored by Bayer. Primary endpoint: Tumor response rate. Started Nov 2004; status: completed.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00661375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00661375.